Ryanodine receptor: a novel therapeutic target against Alzheimer's disease

Researchers of the Institute of Molecular and Cellular Pharmacology (IPMC) have identified the molecular cascade that leads to the deregulation of the Ryanodine receptor (RyR) in Alzheimer’s disease. This research shows that pharmacological or genetic prevention of such deregulation reduces the disease symptoms.